Evidence-Based Reviews

Management of treatment-resistant depression: A review of 3 studies

Author and Disclosure Information

 

References

Ketamine: Review and meta-analysis

Wilkinson et al4 conducted a systematic review and individual participant data meta-analysis of 11 similar comparison intervention studies examining the effects of ketamine in reducing suicidal thoughts.

2. Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150-158.

Study design

  • Review of 11 studies of a single dose of IV ketamine for treatment of any psychi­atric disorder. Only comparison intervention trials using saline placebo or midazolam were included:
  • Individual patient-level data of 298 patients were obtained from 10 of the 11 trials. Analysis was performed on 167 patients who had suicidal ideation at baseline.
  • Results were assessed by clinician-administered rating scales.

Outcomes

  • Ketamine reduced suicidal ideation more rapidly compared with control infusions as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) and HAM-D, with significant benefits appearing on Day 1 and extending up to Day 7. The mean MADRS score in the ketamine group decreased to 19.5 from 33.8 within 1 day of infusion, compared with a reduction to 29.2 from 32.9 in the control groups.
  • The number needed to treat to be free of suicidal ideation for ketamine (compared with control) was 3.1 to 4.0 for all time points in the first week after infusion.

Conclusion

  • This meta-analysis provided evidence from the largest sample to date (N = 298) that ketamine reduces suicidal ideation partially independently of mood symptoms.

While the anti-suicidal effects of ketamine appear to be robust in the above studies, the possibility of rebound suicidal ideation remains in the weeks or months following exposure. Also, these studies only prove a reduction in suicidal ideation; reduction in suicidal behavior was not studied. Nevertheless, ketamine holds considerable promise as a potential rapid-acting agent in patients at risk of suicide.

Continue to: Strategies for augmentation or switching

Pages

Recommended Reading

USPSTF recommends counseling for perinatal depression prevention
MDedge Psychiatry
PTSD, cardiovascular disease link likely caused by higher comorbidity burden
MDedge Psychiatry
Medical students and psychiatry
MDedge Psychiatry
FDA panels back intranasal esketamine for refractory depression
MDedge Psychiatry
Suicide: Igor Galynker
MDedge Psychiatry
Postpartum depression often tricky to diagnose
MDedge Psychiatry
Child suicides rock Kentucky county; lack of access to care burdens rural Arizona
MDedge Psychiatry
Checklists, colleagues key when psychiatric patient overdoses
MDedge Psychiatry
ICU admissions raise chronic condition risk
MDedge Psychiatry
App, role-playing used as interventions
MDedge Psychiatry